Lawrence I. Karsh, MD, Author at Grand Rounds in Urology

Lawrence I. Karsh, MD

The Urology Center of Colorado

Denver, Colorado

Lawrence I. Karsh, MD, is a Co-Founder of The Urology Center of Colorado, where he serves as an attending urologist and Director of Research & Co-Chairman of the Advanced Therapeutic Clinic. He is a certified principal investigator, and has been the principal investigator on over 250 clinical trials. He has authored a number of peer-reviewed publications and serves on the editorial boards for Oncology Live, Urologists in Cancer Care, and Bladder Cancer. He is a fellow of the American College of Surgeons, and an active member of the AUA, SUO, ASCO, SWOG, ACS, and the Denver Academy of Surgeons. He has served on the bladder cancer subcommittee and the advisory board for the SUO Clinical Trials Consortium and is a member of the Bladder Cancer Advocacy Network (BCAN) Think Tank.

Dr. Karsh completed his general surgery training at the University of Colorado Health Sciences Center (UCHSC) and his urology residency at Brigham and Women’s Hospital/Harvard Medical School. He is an Associate Clinical Professor of Surgery at UCHSC. Dr. Karsh participates in many advisory boards for new drug development. He lectures and teaches at scientific meetings throughout the country.

Disclosures:

Talks by Lawrence I. Karsh, MD

Emerging Indications for a Novel Absorbable Hydrogel Spacer

Posted by Lawrence I. Karsh, MD | Jun 2019

Lawrence I. Karsh, MD, addresses the problem of long-term complications following prostate radiation therapy and describes how a novel absorbable hydrogel spacer can alleviate these issues. Additionally, he describes how the spacer can improve conventional radiology, enable dose escalation as well as salvage therapy and hypofractionation, and improve the safety of these patients.

SpaceOAR Hydrogel – Prostate-Rectum Spacing in Radiation Therapy

Posted by Lawrence I. Karsh, MD | May 2018

Lawrence I. Karsh, MD, FACS, discusses the use of SpaceOAR Hydrogel to reduce risk of rectal complications and improve quality of life (QOL) outcomes when treating prostate cancer with radiation therapy. He summarizes supporting clinical evidence, describes the physical application of the gel, and lists players currently offering coverage for the procedure.

Point Counterpoint in ADT—Agonists versus Antagonists

Posted by Lawrence I. Karsh, MD | Apr 2018

Lawrence Karsh, MD, FACS, argues that agonists are effective, sustainable androgen deprivation therapy (ADT) options, and the belief that agonists present a high cardiovascular (CV) risk could be due to selection bias in trials. Conversely, Thomas Keane, MD, argues that patients treated with antagonists have lower CV risk and are more responsive to ADT than those treated with agonists.

Ask the Expert: What Are Some of the Challenges for Urologists Treating Metastatic Castrate Resistant Prostate Cancer Patients?

Posted by Lawrence I. Karsh, MD | Nov 2017

Lawrence Karsh, MD, The Urology Center of Colorado, Denver, Colorado, discusses what some of the...

Ask the Expert: How Do Urologists and Medical Oncologists Differ in Their Approach to Prostate Cancer?

Posted by Lawrence I. Karsh, MD | Oct 2017

Lawrence Karsh, MD, The Urology Center of Colorado, Denver, Colorado, discusses how urologists and...